Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Erpenbeck, Veit J., Popov, Todor A., Miller, David, Weinstein, Steven F., Spector, Sheldon, Magnusson, Baldur, Osuntokun, Wande, Goldsmith, Paul, Weiss, Markus, Beier, Jutta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021787/
https://www.ncbi.nlm.nih.gov/pubmed/27656673
http://dx.doi.org/10.1016/j.dib.2016.08.039
_version_ 1782453392054943744
author Erpenbeck, Veit J.
Popov, Todor A.
Miller, David
Weinstein, Steven F.
Spector, Sheldon
Magnusson, Baldur
Osuntokun, Wande
Goldsmith, Paul
Weiss, Markus
Beier, Jutta
author_facet Erpenbeck, Veit J.
Popov, Todor A.
Miller, David
Weinstein, Steven F.
Spector, Sheldon
Magnusson, Baldur
Osuntokun, Wande
Goldsmith, Paul
Weiss, Markus
Beier, Jutta
author_sort Erpenbeck, Veit J.
collection PubMed
description This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1].
format Online
Article
Text
id pubmed-5021787
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-50217872016-09-21 Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma Erpenbeck, Veit J. Popov, Todor A. Miller, David Weinstein, Steven F. Spector, Sheldon Magnusson, Baldur Osuntokun, Wande Goldsmith, Paul Weiss, Markus Beier, Jutta Data Brief Data Article This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1]. Elsevier 2016-08-29 /pmc/articles/PMC5021787/ /pubmed/27656673 http://dx.doi.org/10.1016/j.dib.2016.08.039 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Data Article
Erpenbeck, Veit J.
Popov, Todor A.
Miller, David
Weinstein, Steven F.
Spector, Sheldon
Magnusson, Baldur
Osuntokun, Wande
Goldsmith, Paul
Weiss, Markus
Beier, Jutta
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
title Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
title_full Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
title_fullStr Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
title_full_unstemmed Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
title_short Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
title_sort data on the oral crth2 antagonist qaw039 (fevipiprant) in patients with uncontrolled allergic asthma
topic Data Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021787/
https://www.ncbi.nlm.nih.gov/pubmed/27656673
http://dx.doi.org/10.1016/j.dib.2016.08.039
work_keys_str_mv AT erpenbeckveitj dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT popovtodora dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT millerdavid dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT weinsteinstevenf dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT spectorsheldon dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT magnussonbaldur dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT osuntokunwande dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT goldsmithpaul dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT weissmarkus dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma
AT beierjutta dataontheoralcrth2antagonistqaw039fevipiprantinpatientswithuncontrolledallergicasthma

Ejemplares similares